Palonosétron (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Palonosétron" in French language version.

refsWebsite

Global rank French rank

4^th place

12^th place

2oxfordjournals.org

1,389^th place

508^th place

1,735^th place

168^th place

719^th place

1,716^th place

2,769^th place

931^st place

222^nd place

129^th place

1sciencedirect.com

149^th place

80^th place

lww.com

journals.lww.com

Rojas C, Stathis M, Thomas AG et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor, Anesth Analg, 2008;107:469-478

medscape.com

(en) Waknine, Yael, « FDA Approvals: Nplate, Aloxi, Vidaza », Medscape, 4 septembre 2008 (consulté le 4 septembre 2008)ly available with registration.

nih.gov

ncbi.nlm.nih.gov

(en) De Leon A, « Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting », Proceedings (Baylor University. Medical Center), vol. 19, n^o 4,‎ 2006, p. 413–6 (PMID 17106506)
Navari RM, Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting — two new agents, J Support Oncol, 2003;1:89-103

oxfordjournals.org

annonc.oxfordjournals.org

Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron, Ann Oncol, 2003;14:1570-1577
Aapro M, Fabi A, Nolè F et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy, Ann Oncol, 2010;21:1083-1088

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

sciencedirect.com

Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial, Lancet Oncol, 2009;10:115-124

wiley.com

onlinelibrary.wiley.com

Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron, Cancer, 2003;98:2473-2482